Gallbladder Cancer Treatment Market By Therapy Type (Chemotherapy, Immunotherapy, Surgical Intervention, Targeted Therapy, Radiation Therapy); By Disease Stage (Early-Stage & Localized Gallbladder Cancer, Advanced, Metastatic & Unresectable Gallbladder Cancer); By Route of Administration (Parenteral/Intravenous Administration, Oral Administration); By End User (Hospitals & Associated Oncology Centers, Specialty Cancer & Hepatobiliary Centers, Academic & Medical Research Institutes, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Gallbladder Cancer Treatment Market: Precision Therapies Gain Ground as Late Diagnosis Sustains Systemic Demand

The Global Gallbladder Cancer Treatment Market was valued at USD 280 million in 2025 and is projected to reach USD 460 million by 2032, expanding at a CAGR of 7.25% during 2026–2032, according to Strategic Market Research.

 

Gallbladder cancer treatment is shaped by late-stage diagnosis, limited surgical, and increasing reliance on systemic therapies for unresectable disease. Although surgery remains the only curative-intent option, most patients require chemotherapy, targeted therapies, or immunotherapy-based approaches due to advanced disease presentation.”

 

The disease represents a small share of global cancers but creates significant treatment demand because of its poor prognosis and requirement for complex multidisciplinary care. In the United States, approximately 12,640 new cases and 4,590 deaths occur annually, with incidence remaining below 2 cases per 100,000 people per year. Globally, gallbladder cancer accounts for approximately 122,500 new cases and 89,000 deaths annually, with women representing nearly 65% of cases. Surgery remains the only curative-intent treatment, especially for early-stage disease, but only around 20% of cases are detected early enough for surgical intervention.

 

Overall, the gallbladder cancer treatment market is shifting from a predominantly surgery-and-chemotherapy model toward multimodal care in which immunotherapy and biomarker-directed treatment are increasingly important, while the high proportion of patients diagnosed with advanced disease continues to sustain demand for systemic therapies and new treatment options.

 

Revenue Battlegrounds — Advanced Disease and Precision Medicine Define the Next Growth Frontier

Therapy Outlook — Chemotherapy Anchors Revenue as Targeted Treatment Accelerates

Chemotherapy Sustains the Largest Treatment Revenue Base

Chemotherapy dominates the therapy-type segment with a 42% share, accounting for USD 117.60 million in 2025 revenue, and is expected to grow at a CAGR of 5.00% during 2026–2032. Chemotherapy remains a core treatment approach in gallbladder cancer by using systemic anticancer drugs to eliminate cancer cells and is widely applied across adjuvant, neoadjuvant, and advanced disease settings. The segment growth is supported by continued use of gemcitabine–cisplatin as the frontline regimen, increasing integration of checkpoint inhibitors such as durvalumab, and adoption of agents including capecitabine, 5-FU, and oxaliplatin in selected patients.

Biomarker Selection Pushes Targeted Therapy to the Growth Frontier

Targeted therapy accounts for an 11% share, equivalent to USD 30.80 million in 2025 revenue, and is projected to record the fastest CAGR of 13.00% during 2026–2032. Targeted therapy is gaining adoption in gallbladder cancer treatment as these drugs are designed to identify and block specific genetic alterations or proteins that drive tumor growth. It is primarily used in advanced, unresectable, or metastatic cases, especially after chemotherapy failure. The treatment approach requires biomarker testing, including next-generation sequencing, to identify eligible patients with actionable mutations, supporting personalized therapy selection and improving treatment precision in advanced disease management.

 

Disease-Stage Outlook — Advanced Disease Concentrates Treatment Demand

Advanced and Unresectable Disease Drives Both Scale and Expansion

Advanced, metastatic, and unresectable gallbladder cancer dominates with a 68% market share, generating USD 190.40 million in 2025 revenue, and is anticipated to grow at a CAGR of 8.00% from 2026 to 2032. This segment represents the highest treatment demand due to the limited role of curative surgery and the increasing reliance on systemic therapies, targeted approaches, and supportive care strategies to manage disease progression and improve patient outcomes.

 

Administration Outlook — Intravenous Delivery Dominates Systemic Care

IV Treatment Captures the Largest and Fastest-Growing Revenue Pool

Parenteral/IV administration dominates the gallbladder cancer treatment market with a 76% share, generating USD 212.80 million in 2025 revenue, and is expected to grow at a CAGR of 7.70% during 2026–2032. This segment remains central to treatment pathways as intravenous delivery enables systemic chemotherapy, immunotherapy combinations, and specialized locoregional interventions for advanced disease. IV regimens such as gemcitabine–cisplatin, checkpoint inhibitor combinations, and second-line therapies support tumor control, while parenteral nutrition provides nutritional support for patients with treatment-related complications or advanced-stage disease.

 

Care-Setting Outlook — Hospitals Lead as Research Institutes Accelerate Innovation

Hospitals Anchor Multidisciplinary Gallbladder Cancer Care

Hospitals and associated oncology centers dominate with a 72% share, representing USD 201.60 million in 2025 revenue, and are projected to expand at a CAGR of 6.70% during 2026–2032. These facilities represent the primary treatment setting for gallbladder cancer due to the need for coordinated hepatobiliary oncology management, where diagnosis, staging, surgical assessment, and systemic therapy decisions must be integrated. Hospitals provide access to advanced imaging, liver and biliary tract surgical expertise, pathology evaluation, chemotherapy, targeted therapies, and emerging immunotherapy approaches used for advanced or unresectable gallbladder cancer. Their role is further strengthened by multidisciplinary tumor boards that evaluate surgical eligibility, recurrence risk, and treatment sequencing across localized and metastatic disease pathways.

Research Institutes Advance the Next Precision-Therapy Wave

Academic and medical research institutes account for a 7% share, equivalent to USD 19.60 million in 2025 revenue, and are projected to record the fastest CAGR of 10.00% during 2026–2032. These institutes are becoming increasingly important in the Gallbladder Cancer Treatment Market by supporting clinical research focused on improving outcomes in a disease where advanced-stage diagnosis and limited treatment options remain major challenges. Research centers are evaluating immunotherapy combinations, targeted approaches against molecular alterations such as HER2 amplification, FGFR pathway changes, and IDH1 mutations, along with genomic profiling and liquid biopsy technologies to identify treatment-responsive patient groups. Expansion of early-phase clinical trials and translational oncology programs is accelerating the development of more personalized treatment strategies for unresectable and metastatic gallbladder cancer.

 

Regional Outlook — Asia-Pacific Combines Disease Burden With Market Momentum

Asia-Pacific Leads Revenue and Sets the Growth Pace

Asia-Pacific represents the leading and fastest-growing regional segment with a 38% market share, generating USD 106.40 million in 2025 revenue, and is anticipated to grow at a CAGR of 8.70% during 2026–2032. The adoption of gallbladder cancer treatments across Asia-Pacific is supported by the region’s higher disease burden, increasing availability of diagnostic imaging, and expansion of specialized hepatobiliary oncology centers. Countries including China, India, Japan, and South Korea are contributing to rising demand for gallbladder cancer surgeries, chemotherapy, targeted therapies, and emerging immunotherapy approaches as healthcare systems improve access to advanced cancer management. Increasing referral networks and greater availability of multidisciplinary oncology services are strengthening treatment pathways for both localized and advanced gallbladder cancer cases.

 

Competitive Landscape — Immunotherapy Scale and HER2 Precision Define Market Leadership

AstraZeneca — Imfinzi Establishes First-Line Immunotherapy Leadership

AstraZeneca is a leading company directly relevant to the gallbladder cancer treatment landscape through Imfinzi (durvalumab), which has become an important first-line immunotherapy for advanced biliary tract cancers, including gallbladder cancer. The FDA approved Imfinzi with gemcitabine plus cisplatin in September 2022 for adults with locally advanced or metastatic biliary tract cancer. The approval was supported by the 685-patient TOPAZ-1 Phase III trial, which demonstrated a reduction in the risk of death compared with chemotherapy alone. An estimated 25% of patients receiving Imfinzi plus chemotherapy were alive at two years versus 10% with chemotherapy alone.

Importantly for gallbladder cancer specifically, TOPAZ-1 included patients with intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer, and subgroup analysis reported an overall-survival hazard ratio of 0.94 for the gallbladder cancer population. The trial was conducted across 105 centers in 17 countries, supporting broad international clinical adoption.

The commercial scale of Imfinzi further strengthens AstraZeneca's position in this treatment ecosystem. Imfinzi generated USD 6.063 billion in worldwide revenue in 2025, up 29% year over year, although this figure covers all approved Imfinzi indications and should not be interpreted as gallbladder-cancer-specific revenue. AstraZeneca specifically reported that gastrointestinal indications, including the TOPAZ-1 biliary tract cancer indication, contributed to Imfinzi growth in emerging markets.

Competitive Field — Targeted and Immunotherapy Portfolios Expand Treatment Choice

• Merck & Co. — Keytruda (pembrolizumab) plus gemcitabine/cisplatin is FDA-approved for locally advanced unresectable or metastatic biliary tract cancer. The 1,069-patient KEYNOTE-966 trial showed median overall survival of 12.7 months versus 10.9 months with chemotherapy alone; Keytruda generated USD 31.68 billion across all indications in 2025, not specifically gallbladder cancer.

• Jazz Pharmaceuticals — Commercializes Ziihera (zanidatamab) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer; Ziihera generated USD 25 million in BTC-specific net product sales in 2025, rising to USD 13 million in Q1 2026 and USD 15 million in Q2 2026.

• Zymeworks — Originally engineered and developed zanidatamab using its Azymetric platform and licenses commercialization rights to Jazz and BeOne; the therapy is approved for HER2-positive biliary tract cancer in multiple jurisdictions, positioning Zymeworks as an important technology and royalty partner in targeted BTC treatment.

• BeOne Medicines — Holds zanidatamab development and commercialization rights across specified Asia-Pacific territories excluding Japan; the therapy received conditional approval in China in May 2025 for previously treated, unresectable or metastatic HER2-high (IHC 3+) biliary tract cancer, expanding access to biomarker-directed treatment in a major Asian market.

• Eli Lilly and Company — Has a historical role in the chemotherapy backbone of biliary tract cancer through gemcitabine development and clinical research and sponsored studies evaluating gemcitabine/cisplatin in inoperable biliary tract cancers involving the gallbladder and bile ducts.

 

Analyst Perspective — Precision Treatment Moves Gallbladder Cancer Beyond Chemotherapy Alone

The gallbladder cancer treatment market is transitioning from a surgery- and chemotherapy-focused approach toward a more biomarker-guided treatment landscape. Growth opportunities are increasingly concentrated around first-line chemo-immunotherapy combinations, HER2-targeted therapies for molecularly selected patients, expanded genomic profiling, and treatment options for unresectable or metastatic gallbladder cancer where surgical intervention is not feasible. The high proportion of patients diagnosed at advanced stages continues to sustain demand for systemic therapies, while molecular characterization is enabling smaller but commercially valuable patient subsets. Companies developing targeted therapies alongside companion diagnostics, improving treatment response rates, and addressing unmet needs in high-incidence regions such as Asia-Pacific are expected to play a larger role as gallbladder cancer management becomes increasingly precision-driven.

 

Gallbladder Cancer Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 280 Million
Revenue Forecast in 2032	USD 460 Million
Overall Growth Rate	CAGR of 7.25% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Therapy Type, By Disease Stage, By Route of Administration, By End User, By Geography
By Therapy Type	Chemotherapy, Immunotherapy, Surgical Intervention, Targeted Therapy, Radiation Therapy
By Disease Stage	Advanced, Metastatic & Unresectable Gallbladder Cancer (Stages III & IV), Early-Stage & Localized Gallbladder Cancer (Stages I & II)
By Route of Administration	Parenteral/Intravenous Administration, Oral Administration
By End User	Hospitals & Associated Oncology Centers, Specialty Cancer & Hepatobiliary Centers, Academic & Medical Research Institutes, Ambulatory Surgical Centers
By Geography	Asia-Pacific, North America, Europe, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Chile, Saudi Arabia, UAE, South Africa
Market Drivers	High advanced-stage disease burden; increasing first-line chemo-immunotherapy use; wider biomarker testing; HER2-directed treatment adoption; expansion of specialized hepatobiliary oncology services
Customization Option	Available upon request